Insider Transactions in Q4 2021 at Nurix Therapeutics, Inc. (NRIX)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,200
-48.27%
|
$34,800
$29.04 P/Share
|
|
Dec 10
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+32.56%
|
$1,200
$1.86 P/Share
|
|
Dec 01
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-2.74%
|
$11,600
$29.13 P/Share
|
|
Dec 01
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+2.67%
|
$2,800
$7.26 P/Share
|
|
Nov 10
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,200
-48.27%
|
$38,400
$32.38 P/Share
|
|
Nov 10
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+32.56%
|
$1,200
$1.86 P/Share
|
|
Nov 01
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-2.74%
|
$13,200
$33.24 P/Share
|
|
Nov 01
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+2.67%
|
$2,800
$7.26 P/Share
|
|
Oct 27
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-2.74%
|
$14,000
$35.0 P/Share
|
|
Oct 27
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+2.67%
|
$2,800
$7.26 P/Share
|
|
Oct 27
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
800
-38.35%
|
$28,000
$35.25 P/Share
|
|
Oct 27
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+27.72%
|
$800
$1.86 P/Share
|
|
Oct 11
2021
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,200
-48.27%
|
$32,400
$27.36 P/Share
|
|
Oct 11
2021
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+32.56%
|
$1,200
$1.86 P/Share
|
|
Oct 01
2021
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-2.74%
|
$11,600
$29.92 P/Share
|
|
Oct 01
2021
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+2.67%
|
$2,800
$7.26 P/Share
|